

# Index

## A

Active pharmaceutical ingredients (APIs), 1, 3–5, 41, 42, 44–48, 50, 55, 56, 58, 59, 69–71, 73, 76–78, 82–84, 86–89, 92, 107, 110, 112, 116–120, 124, 127–147, 170, 171, 173, 178, 179, 192, 193, 207, 209–212

Adam and Gibbs (AG) model, 123

Aeroperl 300, 140, 141

Aging, 65, 125, 126

AGV equation, 198

Amino acid, 95

Ammonium alums, 89

Amorphization, 3, 6, 42, 44, 50, 58, 61, 76, 77, 79, 88, 90–94

Amorphous, 1, 9, 41, 69, 107–127, 159

Amorphous drug phase separation, 173, 174, 202, 206, 207, 211

Amorphous drugs, 4, 41–65, 75, 148, 217

Amorphous halo, 15

Amorphous solid dispersions (ASDs), 5, 46, 48, 49, 51, 52, 54–65, 71–74, 77, 78, 82, 83, 86, 88, 117, 127–136, 160, 161, 164–166, 168–175, 179, 180, 185–188, 190–194, 196–202, 206–210, 212, 215, 217

Amorphous solids, 3, 4, 15, 22, 25, 28, 45–47, 50, 51, 56, 60, 63, 73, 89, 91, 93, 95

Amorphous solubility, 60, 163, 164, 166–170, 174, 202, 205, 207, 210

Amorphous state, 3, 4, 25–27, 29, 31, 46, 48, 50, 63, 72, 73, 79, 85, 91–95, 107–128

Angell plot, 113, 114

Anti-plasticizing effect, 116, 132, 136

Anti-solvent precipitation, 91

Aperiodic crystal, 11, 12, 15

Aripiprazole, 76

Arrhenius equation, 114

Avrami-Avramov plot, 121, 122

Avramov approach, 119, 121, 122

## B

Bicalutamide, 57, 83, 124, 132

Binary drug-drug mixtures, 136–139

Bioavailability, 1, 6, 41–46, 48–58, 61–63, 87, 92, 138, 145, 159, 161, 163, 164, 168, 169, 171, 174, 185, 186, 189, 190, 196, 197, 202, 204, 205, 210, 211, 217

Biopharmaceutical, 1, 42, 63, 77, 185, 188, 196, 209, 212, 217

Biopharmaceutical classification system (BCS), 2, 42–44, 62, 185, 186, 188, 209

Biopharmaceutical drug disposition classification system (BDDCS), 185, 189

Bond angles, 18, 24

Bravais lattices, 14, 15, 19

Broadband dielectric spectroscopy (BDS), 118, 140, 142, 145, 147, 148

## C

Caffeine, 91

Carbamazepine, 57, 59, 61, 72, 73, 83, 85, 88

Carbon dioxide (CO<sub>2</sub>), 71, 74, 83–85

Celecoxib, 58, 60, 63, 82, 88, 117, 120, 122, 123, 133–135

Characteristic crystallization time, 119

Classical nucleation theory (CNT), 107–109, 111, 112, 115, 116, 140

- Co-amorphous formulation, 136, 137, 139  
Co-current flow, 82  
Co-grind, 95, 138, 143  
Colloidal silicon dioxide, 82, 143  
Compression, 25, 27, 145, 147, 148, 174, 194  
Condis phase, 28, 29  
Configurational enthalpy, 111  
Configurational entropy, 110, 111, 115, 187, 188, 196, 203, 209  
Confocal microscopy, 18  
Conformational disorder, 25, 29  
Conformational order, 28  
Conservation of heat, 181  
Conservation of mass, 182  
Continuous growth model, 109  
Continuous random network (CRN), 23–25  
Conveying screw, 176–179, 215  
Cooling rate, 3, 4, 27, 77  
Coordination number, 19  
Co-precipitation, 64, 128  
Couchman-Karasz (C-K) equation, 130, 131  
Counter-current flow, 82  
Coupling coefficient, 120–123  
Covalent bonding, 89  
Critical pore diameter, 141  
Critical pressure, 83  
Critical temperature, 83  
Cryogrinding, 93  
Crystal, 2, 9, 42, 77, 108, 163  
Crystal growth, 3, 6, 50, 55, 108–110, 113, 116–118, 134, 140, 148, 163  
Crystal growth rate, 109, 111, 113, 116, 120, 127, 134  
Crystalline, 3, 9–14, 44, 71, 107, 161  
Crystalline solids, 15, 93  
Crystallization, 3, 21, 71, 107–127, 161  
Crystallization-inhibiting, 163  
Crystallization inhibition, 61, 135, 143, 199, 203, 204, 210  
Crystallization rate, 95, 108, 117, 118, 121, 132–134, 145, 146  
Crystallization tendency, 110, 127, 134, 187, 188, 196, 200, 203  
Crystal solvates, 89, 91, 93  
Crystal structure, 9, 12, 30, 46, 90–92, 94, 95  
Cyclone, 81, 180
- D**  
Debye-Stokes-Einstein (DSE) equation, 113  
Defects, 28, 93, 109  
Dehydration, 89–92  
Desolvation, 89, 90  
Differential scanning calorimetry (DSC), 29, 51, 60, 72, 73, 76, 90, 112, 120, 129, 131, 140, 141, 145, 200, 209, 210  
Diffusion chamber, 166  
Diffusion coefficient, 2, 42, 55, 56, 109, 113  
Dipole-dipole forces, 116  
Dispersive mixing, 69, 176, 177, 179  
Dissolution, 1, 41, 70, 128, 159  
Dissolution drug, 3, 42, 44, 46, 48, 52, 54, 57, 60, 61, 70–72, 170, 185  
Dissolution kinetic, 128, 130, 193, 201  
Dissolution rate, 2, 4, 42, 43, 45, 48–52, 55–57, 59, 60, 62, 63, 65, 72, 73, 76, 78, 85, 144, 160, 170, 186, 202  
Distributive mixing, 176, 177  
Domperidone, 76  
Dosage forms, 41, 42, 44, 45, 48, 49, 57, 63, 71, 74, 159, 169, 186, 189, 193, 196, 203, 204, 209  
3D printed films, 76  
3D printing technology, 74, 76  
Drug dissolution rate, 1, 41, 42, 54, 56, 60  
Drug-polymer interactions, 61, 117, 130, 131, 134, 147, 188, 191, 201  
Drug-polymer miscibility, 61  
Drug-polymer solubility, 49, 128  
Drug solubility, 1, 2, 43–50, 53, 57–59, 64, 65, 82, 197, 200  
Drug solubility in polymer, 200  
Drying chamber, 79, 80, 180  
Drying kinetics, 180, 181, 183, 185, 216  
2-D/surface nucleation growth model, 109, 110
- E**  
Elastic strain, 93  
Electrospinning, 85–87  
Electrospraying, 85–87  
Electrostatic particle collector, 81  
Endothermic, 72, 90, 129  
Energy barrier for nucleation, 109  
Environmental equivalency (EE), 216  
Ethanol, 29, 31, 192, 203, 204, 210  
Etoricoxib, 117, 145  
Etravirine, 64, 88, 128  
Excipients, 42–44, 46, 48, 49, 73, 82, 83, 92, 112, 116, 117, 120, 127, 134–136, 145, 146, 175, 178, 195  
Exothermic, 90  
Ezetimibe, 63, 124, 125, 139–141, 143

**F**

Felodipine, 58, 60, 72, 83, 88, 113, 117, 120, 130, 133, 134, 162–167, 169, 170  
Fenofibrate, 64, 86, 88, 128, 143  
Fictive temperature, 123, 198  
Film casting, 76, 88  
Flory-Huggins, 191, 201, 210  
Flory-Huggins (FH) interaction parameter, 130, 131  
Flory-Huggins theory, 130, 131  
Flutamide, 78  
Food effect, 189, 190  
Formation of amorphous drug nanoparticles, 169, 196, 206, 210  
Formulation (design), 42, 73, 196, 197, 203, 207, 209, 211  
Fox equation, 198  
Fragile glass formers, 114  
Fragility parameter, 114  
Free volume, 27, 31, 84, 135, 136, 176, 214, 215  
Freeze-dryer, 79  
Freeze-drying, 62, 77–79, 82, 91, 93–95, 190  
Freezing, 77, 78  
Fused deposition modelling (FDM), 74, 76

**G**

Gibbs free energy, 4, 108, 110, 130  
Glacial state, 25  
Glass, 3, 15, 46, 69, 110, 186  
Glass-formers, 21, 23–25, 114  
Glass network, 23  
Glass solution, 46, 51  
Glass suspension, 46  
Glass transition, 18, 28, 29, 78, 115, 118, 128, 131, 132, 194, 198  
Glass transition temperature, 3, 21, 25, 29, 52, 69, 71, 78, 91, 93, 94, 113, 131, 132, 136, 139–141, 186–188, 192, 196–198, 209, 211  
Glassy state, 4, 113, 118, 122–126  
Gordon-Taylor (G-T) equation, 51, 130, 131, 136, 198  
Grinding, 92–94, 189  
Griseofulvin, 57, 64, 83, 86, 87, 94, 121, 122, 187

**H**

Heterodimer, 117, 137–139  
Heterogeneous nucleation, 22, 108  
Hexagonal, 29–31

High speed electrospinning, 86  
Homodimer, 117, 135, 146  
Homogeneous nucleation, 25  
Hot-melt extrusion (HME), 6, 59, 61–64, 69–74, 76, 84, 170, 174, 175, 178, 190–197, 199, 200, 203, 210, 212–215  
Hydrates, 44, 89–92, 209  
Hydrophobic capture, 171, 173, 202, 206, 207  
Hydrophobicity, 163, 171, 185

**I**

Ice nucleation, 77  
Indomethacin, 26, 57, 60, 61, 76, 83, 110, 113, 120, 122, 130, 133, 135–139, 146, 161, 169  
Induction time, 60, 119, 121, 122  
Inelastic X-ray scattering, 21  
Inorganic oxide glasses, 22, 27  
Inorganic salts, 89, 92, 93  
Interfacial free energy, 108, 110, 112, 113, 140  
Interferometric scattering microscopy, 18  
Intermolecular potential, 116  
Intrinsic dissolution rate (IDR), 54  
In vitro characterization, 211  
In vivo characterization, 211  
In vivo dissolution, 56, 57, 159–161, 169–171, 185, 190, 197, 203, 204  
Ionic plastic crystals, 30  
Isomerization, 25, 32  
Isomers, 95, 145  
Itraconazole, 57, 59, 64, 73, 74, 86–88, 120, 122, 147

**J**

Johari-Goldstein relaxations, 115

**K**

Ketanserin, 86  
Kolmogorov-Johnson-Mehl-Avrami (KJMA) equation, 119

**L**

$\alpha$ -Lactose, 95  
Lacunary phase, 90  
Lattice theory, 191, 201, 210  
Levetiracetam, 74  
Liquid atomization, 79  
Liquid crystal, 28–30, 32  
Liquid-crystal interface, 109, 112, 113

Liquid-crystal transition, 3  
 Liquid-glass transition, 3, 113  
 Liquid-liquid phase separation (LLPS),  
   167–171, 174, 185, 186, 196, 197, 202,  
   206, 207, 210, 211  
 Liquid structure, 19  
 Log $P_{obs}$ , 185, 209  
 Long-range ordering (LRO), 4  
 Lyophilization, 77, 78  
 Lyotropic, 29, 30

## M

Manganous oxalate dihydrate, 89  
 Master plot predications, 123, 125  
 MCM-41, 141–143  
 Mechanical property, 44, 71, 92, 174, 193–196  
 Mechanical stress, 5, 90, 110, 145, 147  
 Mechanical treatment, 27, 80, 89, 91–95  
 Meglumine, 82  
 Membrane permeability, 1, 43  
 Mesophases, 28, 29, 31, 32, 95  
 Mesoporous silica, 141, 142, 144  
 Metastable, 29, 46, 50, 90, 92, 95, 118, 161,  
   167, 168  
 Micro-suspension, 170  
 Milling, 4, 71, 93, 94, 137–139, 174, 190, 201  
 Miscibility, 46, 51, 60, 61, 70, 71, 83, 127–132,  
   167, 168, 191, 201, 202  
 Miscibility gap, 167, 202  
 Mixing block, 176–178  
 Mobility global, local, 118  
 Modified random network (MRN), 23, 24  
 Modulated phases, 11, 12  
 Modulated structures, 11–13  
 Molecular interactions, 61, 116, 127, 133–135,  
   137–139, 143  
 Molecular mobility, 4, 28, 84, 108, 110, 113,  
   117, 127, 130, 132–135, 137, 143, 148,  
   186–188, 196–198, 203, 209  
 Mollier diagram, 183

## N

Nanocrystals, 25, 29  
 Nanoparticles, 44, 160, 164, 169, 174, 185,  
   186, 196, 197, 203, 204, 206, 210, 211  
 Nanopores, 140  
 Nanoscale confinement, 140, 142  
 Nano-suspension, 170, 171  
 Naproxen, 71, 83, 136, 137, 139, 143, 147  
 Nematic, 29, 30  
 Neusilin US2, 140, 141

Neutron scattering (NS), 17  
 Noyes-Whitney equation, 2, 55, 160  
 Nuclear magnetic resonance (NMR), 22, 133  
 Nucleation, 3, 6, 25–27, 50, 51, 55, 60, 61, 77,  
   94, 95, 107–113, 116–119, 127, 140,  
   148, 163  
 Nucleation rate, 26, 27, 55, 107, 108, 111,  
   116–118  
 Nuclei growth, 94

## O

Octaacetylmaltose (acMAL), 134, 135  
 Oral dosage forms, 41, 42, 48, 64, 77  
 Orientational disorder, 25, 32  
 Orientational order, 18, 29, 30  
 Orientationally disordered crystals (ODIC),  
   30–32

## P

Pair correlation function (PCF), 16  
 Pair distribution function (PDF), 16–18, 27, 94  
 Particle size, 2, 42, 44, 47, 56, 71, 89–91, 170,  
   174, 193, 194, 207, 209, 211  
 Penrose tilings, 14, 15  
 Periodic close packing, 20, 21  
 Periodic crystals, 9, 11, 12, 14  
 Permeability, 1, 2, 41–44, 49, 51, 52, 57, 58, 62,  
   65, 73, 185, 186, 188–190, 209  
 Pharmaceutical properties, 185  
 Phase-diagram of API-polymer system, 129  
 Phase separation, 27, 51, 117, 146, 147,  
   167–169, 173, 174, 183, 188, 191, 196,  
   201, 202, 206, 207, 211, 214  
 Physical instability, 49, 107–148, 187, 188, 211  
 Physicochemical, 1–3, 41, 42, 48, 56, 62, 65,  
   74, 83, 185, 188, 196, 209, 212  
 Piroxicam, 83, 85, 137, 139  
 pKa, 3, 186, 188, 205, 209  
 Plastic crystals, 28–32  
 Plastic deformation, 93, 196  
 Plasticizers, 71, 74, 78, 84, 117, 132, 178, 198,  
   199  
 Polyacryloxybenzoic acid, 31  
 Polyamorphism, 27, 28, 89  
 Polyamorphs, 26–28, 94  
 Polymer plasticization, 83  
 Polymorphism, 27, 54, 89, 92, 94  
 Porosity (of freeze dried material), 54, 78, 194  
 Porous glass, 89  
 Powder diffraction methods, 18  
 Precipitation, 4, 46, 48, 51, 91, 94, 170, 190

- Pressure nozzle (atomization), 79  
Primary drying, 77, 78  
Probuconol, 145, 146  
Process-induced crystallization, 146  
Process scale up, 212–214  
Psychrometric chart, 183, 184
- Q**  
Quasicrystalline structures, 14  
Quasicrystals, 11, 14  
Quench-cooling, 93, 94, 137, 138
- R**  
Radial distribution function (RDF), 17  
Random close packing (RCP), 20–22, 25, 27  
Recrystallization, 5, 6, 49, 54, 89, 94, 95, 111, 117, 123, 125, 128, 132, 134, 139, 140, 142, 145–147, 209  
Relative humidity (RH), 73, 182  
Relative solvent saturation, 182  
Rigid network, 89  
Rotary nozzle (atomization), 79  
Rule of degree of fill, 215  
Rule of heat transfer, 215
- S**  
SBA-15, 141, 143, 144  
Scale-up, 46, 83, 181, 211–216  
Screw configuration, 69, 176–178, 214, 215  
Screw diameter, 176, 214, 215  
Screw-dislocation model, 109  
Screw flight distance, 176, 214  
Screw helix angle, 176  
Screw pitch, 176, 178  
Secondary drying, 78, 180  
Secondary relaxations, 113–115, 118, 122, 123  
Simha-Boyer rule, 198  
Similar environment, similar exposure, 213, 215  
Simvastatin, 82, 94, 137, 139  
Small X-ray Scattering (SAXS), 21, 22  
Smectic, 29, 30  
Smith-Topley effect, 90  
Sol-gel, 27  
Solid solution  
    continuous, 46  
    discontinuous, 46  
    interstitial, 47  
Solubility improvement, 43–49, 57, 59, 62  
Solubilization, 2, 4, 71, 83, 160, 169, 189, 197, 209, 210  
Solute, 46, 47, 50, 77, 78, 184, 185  
Solvent, 29, 46, 47, 49, 50, 56, 70, 77–79, 82–84, 88, 90, 92, 139, 166, 167, 179–185, 190–193, 197, 204, 209, 210, 216  
Solvent evaporation, 61, 88, 137, 143, 183, 190, 210  
Spatial inhomogeneity, 21  
Specific mechanical energy, 215  
Specific molecular interactions, 133, 139  
Spin-coating, 88  
Spinodal decomposition, 168, 202  
Spray drying, 6, 46, 63, 64, 77, 80, 86, 88, 93, 95, 120, 121, 128, 136, 137, 143, 174, 180–185, 190–195, 197, 200, 203, 212, 216  
Spritam, 74  
Stability, 3, 4, 6, 25, 28, 31, 32, 43, 44, 48, 49, 61, 62, 73, 76, 82, 83, 86, 89, 90, 107, 116–127, 134–136, 139, 140, 142–144, 146, 147, 161, 183, 186–188, 190–192, 197–199, 203, 209, 211, 214, 217  
Stability of amorphous, 107, 116–118, 127, 142, 144–148, 187, 200, 209  
Starve fed, 178, 215  
Steepness index, 114  
Stefan-Skapski-Turnbull relation, 112  
Stokes-Einstein (SE) equation, 113  
Strength of drug-polymer interactions, 116, 132–134, 171  
Strong glass formers, 114  
Structural disorder, 12, 15, 23, 24, 28  
Structural  $\alpha$ -relaxation, 113–115, 118, 123–125, 140, 141  
Supercooled liquid state, 3, 4, 25, 91, 113, 114, 118, 119, 122, 123, 134  
Supercooling, 18, 21, 29, 94, 111, 123, 134, 145  
Supercritical carbon dioxide, 83–85  
Supercritical fluid (SCF), 71, 83–85, 190  
Supersaturation, 50, 51, 54–56, 60, 61, 63, 129, 130, 161–165, 167–169, 186, 187, 200, 203, 204, 206, 207, 210  
Surface free energy, 89, 140  
Surface tension, 57, 82, 85, 88, 112, 140, 180, 181, 216
- T**  
Tableting, 71, 92, 147  
Tablets, 2, 55, 63, 64, 71–73, 76, 92, 146, 161, 170, 175, 193, 194, 197, 213, 216  
Tautomeric equilibrium, 117  
Tautomerisation, 117, 145  
Taylor cone, 85  
Tert-butanol (TBA), 78

- Tetrahedral liquid, 25  
Thermodynamic driving force, 108–110, 112, 148  
Thermodynamics, 2, 4, 5, 29, 31, 44–46, 49, 50, 80, 83, 84, 89, 93, 94, 107, 108, 110–113, 116–118, 123, 128, 129, 148, 167, 181–183, 187, 196, 200, 203, 210, 214  
Thermo-gravimetric analysis, 90  
Thin film (as fast dissolving drug delivery systems), 27, 76, 87–89  
Three dimensional printing (3d printing), 74–76  
Translational order, 28–30  
Twin screw extruder (TSE), 72, 175, 178, 193, 215  
Twin screws, 175  
Two-fluid nozzle (atomization), 79
- U**  
Ultrasonic nozzle (atomization), 79  
Uranyl oxalate, 89
- V**  
Vapor condensation, 94  
Vapor deposition, 94, 190  
Vapour pressure, 78, 90, 91, 182, 183, 191, 192  
Vibrating mesh technology, 79  
Vibrational spectra, 94
- Viscosities, 2, 26, 56, 60, 71, 74, 77, 79, 82, 83, 86, 88, 94, 113, 115, 135, 177–181, 192, 214, 216  
Vogel-Fulcher-Tammann-Hesse (VFTH) equation, 114  
Voronoi-Dirichlet polyhedra (VDP), 19  
VTF equation, 198
- W**  
Water, 1, 3–5, 25, 31, 45, 46, 52, 56, 58, 62, 71, 73, 74, 76–78, 82, 83, 85, 87, 89–91, 93, 117, 118, 144, 159, 160, 163, 167–173, 185, 186, 189, 190, 192, 206, 207, 209, 216, 217  
Wide X-ray Scattering (WAXS), 22
- X**  
X-ray Absorption Fine Structure (XAFS), 22  
X-ray diffraction, 15, 18, 29, 89, 119, 209  
X-ray free-electron lasers, 18  
X-ray powder diffraction (XRPD), 29, 60, 90  
X-ray scattering, 17, 21
- Z**  
Zeolites, 58, 89, 90  
ZipDose<sup>®</sup> technology, 74